APA (7th ed.) Citation

Reck, M., & Thomas, M. (2017). Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung cancer, 112, . https://doi.org/10.1016/j.lungcan.2017.07.038

Chicago Style (17th ed.) Citation

Reck, Martin, and Michael Thomas. "Outcomes in Patients with Aggressive or Refractory Disease from REVEL: A Randomized Phase III Study of Docetaxel with Ramucirumab or Placebo for Second-line Treatment of Stage IV Non-small-cell Lung Cancer." Lung Cancer 112 (2017). https://doi.org/10.1016/j.lungcan.2017.07.038.

MLA (9th ed.) Citation

Reck, Martin, and Michael Thomas. "Outcomes in Patients with Aggressive or Refractory Disease from REVEL: A Randomized Phase III Study of Docetaxel with Ramucirumab or Placebo for Second-line Treatment of Stage IV Non-small-cell Lung Cancer." Lung Cancer, vol. 112, 2017, https://doi.org/10.1016/j.lungcan.2017.07.038.